Does ABCL pay a dividend and is it safe?

AbCellera Biologics Inc. (ABCL) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ABCL / dividends

ARQT (54) LQDA (36) TNGX (45) INDV (51) ⌘ Pro Terminal →

AbCellera Biologics Inc. (ABCL) Dividend Safety Gauge & 10-Year DRIP Compounder

$11.12 -9.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.91

AbCellera Biologics Inc. (ABCL) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.97B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABCL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, AbCellera Biologics Inc. (NASDAQ: ABCL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.12 (-9.37% 1D, market cap $3.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABCL ranks #380 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABCL compare to ARQT and LQDA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABCL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.5%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and LQDA (Liquidia Corporation) posts a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABCL?

▼

Per ABCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703057), AbCellera Biologics Inc. generated $75.1M in revenue (+160.6% YoY), -$146.4M in net income, and -$174.1M in free cash flow against $1.36B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.91 (-1.88%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABCL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY ABCL SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 6.60 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$12.64-5.6% Next Q

Q2 (-2Q)

Grade D$11.93+1.3% Next Q

Q3 (-1Q)

Grade D$12.08-7.9% Next Q

Current

Grade D$11.12-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABCL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABCL currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.31) and Max Pain ($11.68) forces dealer call-delta covering toward $15.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABCL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABCL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABCL)

✓Walkthrough of ABCL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABCL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +142.27%▲ ASCENDING CHANNEL

2026-11-03O $13.08H $13.08L $11.12C $11.12VOL 3.88M

RES: $17.22SUP: $6.45SMA50: $12.31SMA200: $6.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABCL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABCL Butterfly Map → + Track ABCL →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +160.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABCL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABCL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABCL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABCL)

Health Care Rank #380 of 1015 ⚔️ ARQT vs ABCL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABCL vs. ARQT, LQDA, TNGX, INDV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AbCellera Biologics Inc. (ABCL) ranks #380 by composite RQD confidence (44/100, grade D) and #182 by equity capitalization ($3.97B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. ARQT currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ABCL at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABCL ACTIVE AbCellera Biologics Inc.	D	44/100	—	—	-20.5%	-9.37%	$3.97B	Benchmark Subject
ARQT Arcutis Biotherapeutics Inc.	D+	54/100	—	90.2%	-3.0%	-2.53%	$4.03B	/arqt-vs-abcl →
LQDA Liquidia Corporation	D-	36/100	—	—	-12.6%	-7.12%	$4.03B	/lqda-vs-abcl →
TNGX Tango Therapeutics Inc.	D	45/100	—	—	-28.9%	-4.22%	$3.83B	/tngx-vs-abcl →
INDV Indivior Pharmaceuticals Inc.	D	51/100	19.8x	80.2%	62.2%	+0.34%	$4.17B	/indv-vs-abcl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001703057 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AbCellera Biologics Inc. (ABCL) reported GAAP revenue of $75.1M (+160.6% vs. FY2024 revenue of $28.8M , and +97.6% cumulative change since FY2023) , GAAP net income of -$146.4M, operating cash flow of -$131.3M, and free cash flow of -$174.1M (+6.9% YoY). On the balance sheet, ABCL closed FY2025 with $1.36B in total assets against $0 in total debt (Altman Z-Score: 6.60, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$75.1M	-$146.4M	-$131.3M	-$174.1M	$1.36B	—
FY2024 (FY)	2024-12-31	$28.8M	-$162.9M	-$108.6M	-$187.0M	$1.36B	—
FY2023 (FY)	2023-12-31	$38.0M	-$146.4M	-$43.9M	-$43.9M	—	—

3. ABCL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABCL compare to ARQT and LQDA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABCL?

Where is ABCL trading relative to its 50-day, 200-day, and 52-week technical levels?

ABCL last traded at $11.12 (-9.37% on volume of 3,037,180 shares), positioning the stock -9.67% below its 50-day simple moving average ($12.31) and +61.39% above its 200-day simple moving average ($6.89). Across its 52-week range of $2.74 to $15.02, ABCL sits at the 68.2% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.73 to $12.51).

Direct Sub-Reports: ABCL RQD Cockpit ABCL 12M Forecast ABCL Earnings & Move ABCL Dividends & DRIP ABCL Insiders & 13F ABCL Whale Options ABCL Profit Sankey ABCL News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

ABCL — AbCellera Biologics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AbCellera Biologics Inc. (ABCL) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.12 (-9.37% 1D, market capitalization $3.97B).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -20.5%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -4.11%.
Whale 13F & Options Flow (12/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 6.60, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AbCellera Biologics Inc. (ABCL) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. Gross margin is 0% per the market data, and operating margin is -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AbCellera Biologics Inc. (ABCL) reported $75.1M in annual revenue (up from $28.8M in FY2024, +160.6% YoY) and -$146.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($38.0M revenue, -$146.4M net income) through FY2025, ABCL scaled operating cash flow to -$131.3M and free cash flow to -$174.1M, backed by $1.36B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.11% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $2.74 – $15.02 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE, butterfly_links is empty, and proprietary_signals is empty. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The one ripple a prospective investor should monitor is the October 13, 2026 lock-up expiry noted in the news feed, which could add supply to the float.

Key Question #1: Can ABCL sustain or expand its -60.0% operating margin and -20.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $75.1M and free cash flow of -$174.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ABCL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABCL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AbCellera Biologics Inc. (ABCL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABCL Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus

Yahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Certain Common Stock of AbCellera Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.

www.marketscreener.com report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

UBS Initiates AbCellera Biologics at Buy With $18 Price Target

Yahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Is AbCellera Biologics (ABCL) Undervalued On Positive Phase 2 ABCL635 Results?

Simply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

AbCellera Biologics (ABCL) Institutional Ownership 2026

MarketBeat report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

AbCellera Biologics (NasdaqGS:ABCL) Stock Forecast & Analyst Predictions

Simply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 1d ago

AbCellera (ABCL) Sinks -6.94% as Volume Spikes on Downside 2026-10-17 - Demand Zone

https://www.siam.in/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

AbCellera Biologics (ABCL) Shares Advance 4.37% to $12.54, Nearing Upper Range - Institutional Sentiment

https://www.dars.gov.et/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABCL Bull vs. Bear Conversation Board — What's Your Call at $11.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABCL 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $14.60 (+19.0%)

📌 Pinned Debate

Positive ABCL635 Phase 2 read-through and a UBS Buy initiation at an $18 target point to upside from the $12.27 price.

Don't sleep on ABCL's setup in Health Care. Positive ABCL635 Phase 2 read-through and a UBS Buy initiation at an $18 target point to upside from the $12.27 price.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (44/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $10.06 (-18.0%)

Spot @ $12.27

Negative ROIC of -20.5% and FCF of -$174.1M in FY 2025 show a cash-burning business priced at a $4.24B market cap.

Fading this rally in ABCL at $12.27. Negative ROIC of -20.5% and FCF of -$174.1M in FY 2025 show a cash-burning business priced at a $4.24B market cap.. With a beta of 1.0 and the stock sitting at $12.27 (52-wk range $2.25–$15.02), the easy multiple expansion is already priced in.